澳华内镜：2025年全年净利润同比预减44.89%—61.69%

Core Viewpoint - The company, Australia Huaren Endoscopy, anticipates a significant decline in net profit for the year 2025, projecting a decrease of 44.89% to 61.69% compared to the previous year, primarily due to changes in sales structure and increased operational costs despite revenue growth [1] Group 1: Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between 8.05 million and 11.58 million, indicating a substantial year-on-year decrease [1] - The anticipated net profit excluding non-recurring gains is expected to be between -10.53 million and -7 million [1] Group 2: Revenue and Sales Growth - The company has achieved significant growth in overseas sales due to successful market entry and business expansion, contributing to a slight overall revenue increase compared to the previous year [1] - The successful launch of the new flagship model AQ400 has further contributed to revenue growth [1] Group 3: Cost and Profitability Challenges - A phase change in the product sales structure has led to a decline in overall gross margin [1] - The company has increased investments in marketing, brand enhancement, product development, and new technology, resulting in high sales, management, and R&D expenses, which have negatively impacted profitability despite revenue growth [1] Group 4: Non-Recurring Gains - The company expects non-recurring gains to impact net profit by approximately 18.58 million, primarily from government subsidies and investment income, compared to 27.29 million in the same period last year [1] Group 5: Comparative Financial Data - The financial data from the previous year serves as a low comparative base, leading to significant fluctuations in related ratios for the current reporting period [1]